Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008–2013

WHO: World Malaria Report 2011. 2011, Geneva: World Health Organization

Ministry of Health, People’s Republic of China: From Malaria Control to Elimination: a Revised National Malaria Strategy 2010–2015. 2009, Beijing: Ministry of Health, 2-4.

Ministry of Health, People’s Republic of China: Malaria Elimination Action Plan 2010-2020(in Chinese). 2010, Beijing: Ministry of Health, 1-2.

Cotter C, Sturrock HJW, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RGA: The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet. 2013, 382: 900-911. 10.1016/S0140-6736(13)60310-4.

Petersen I, Eastman R, Lanzer M: Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett. 2011, 585: 1551-1562. 10.1016/j.febslet.2011.04.042.

Cui L, Yan G, Sattabongkotc J, Chen D, Cao Y, Fan Q, Parkera D, Sirichaisinthopg J, Su XZ, Yang H, Yang Z, Wang B, Zhou G: Challenges and prospects for malaria elimination in the Greater Mekong. Acta Trop. 2012, 121: 240-245. 10.1016/j.actatropica.2011.04.006.

Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM: Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007, 77: 79-87.

Price RN, Douglas NM, Anstey NM: New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009, 22: 430-435. 10.1097/QCO.0b013e32832f14c1.

Rieckmann KH, Davis DR, Hutton DC: Plasmodium vivax resistance to chloroquine?. Lancet. 1989, 2: 1183-1184.

Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F: Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis. 2011, 53: 977-984. 10.1093/cid/cir631.

World Health Organization: Method for Surveillance of Antimalarial Drug Efficacy. 2009, Geneva: World Health Organization, 12-82.http://www.who.int/malaria/resistance,

Bureau for Disease control and prevention, Ministry of Health, People’s Republic of China: Malaria Control Manual (in Chinese). 2007, Beijing: People’s Health Publishing Company, 33-42.

Yang HL, Yang Y, Yang PF: Monitoring Plasmodium falciparum chloroquine resistance in Yunnan Province, China, 1981–2006. Acta Trop. 2008, 108: 44-49. 10.1016/j.actatropica.2008.08.010.

Huang T, Wang X, Li X, Huang Y, Zeng C, Zhang S, Fu W, Zhang Z, Zhang G: Studies on identification of circumsporozoite protein genotyping of Plasmodium vivax] (in Chinese). Chin J Parasitol Parasit Dis. 2000, 18: 272-276.

Organization WH: Guidelines for the Treatment of Malaria. 2006, Geneva: World Health Organization, 1-66.

Stepniewska K, White NJ: Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malar J. 2006, 5: 127-10.1186/1475-2875-5-127.

Wei D, Li GL, Huang YS, Dai CF, Chen GL: The analysis of clinical characteristics for 47 patient cases of chloroquine-resistant Plasmodium vivax (in Chinese). Southwestern Defence Med. 2000, 10: 86-87.

Yang XM, Yang MQ, Huang JW, Zhao FX: The clinical study on Plasmodium vivax chloroquine sensitivity (in Chinese). Chinese J Parasitic Dis Control. 1996, 9: 226-227.

Liang GL, Su XD, Wang J, Zhang ZX: Evaluation of the sensitivity of vivax malaria to chloroquine in the City of Laza, Myanmar (in Chinese). J Pathogen Biol. 2010, 5: 362-372.

Lu F, Gao Q, Xia H, Tao Z, Cao J, Gu Y, Zhou H, Jin X, Udomsangpetch R, Sattabongkot J: In vitro sensitivity test of Plasmodium vivax to chloroquine in center part of China (in Chinese). Chin J Schisto Control. 2006, 18: 265-267.

Myat Phone K, Myint O, Myint L, Thaw Z, Kyin Hla A, Nwe Nwe Y: Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg. 1993, 87: 687-10.1016/0035-9203(93)90294-Z.

Marlar T, Myat Phone K, Aye Yu S, Khaing Khaing G, Ma S, Myint O: Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg. 1995, 89: 307-308. 10.1016/0035-9203(95)90556-1.

Barnadas C, Kent K, Timinao1 L, Iga1 J, Gray L, Siba1 P, Mueller I, Thomas P, Zimmerman P: A new high-throughput method for simultaneous detection of drug resistance associated mutations in Plasmodium vivax dhfr, dhps and mdr1 genes. Malar J. 2011, 10: 282-10.1186/1475-2875-10-282.

Guthmann JP, Pittet A, Lesage A: Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. Trop Med Int Health. 2008, 13: 91-98. 10.1111/j.1365-3156.2007.01978.x.

Baird JK: Chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother. 2004, 48: 4075-4083. 10.1128/AAC.48.11.4075-4083.2004.

Lee KS, Kim TH, Kim ES: Chloroquine-resistant Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg. 2009, 80: 215-217.

Kurcer MA, Simsek Z, Zeyrek FY: Efficacy of chloroquine in the treatment of Plasmodium vivax malaria in Turkey. Ann Trop Med Parasitol. 2004, 98: 447-451. 10.1179/000349804225021343.

Teka H, Petros B, Yamuah L: Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J. 2008, 7: 220-10.1186/1475-2875-7-220.

Santana Filho FS, Arcanjo AR, Chehuan YM: Chloroquine resistant Plasmodium vivax, Brazilian Amazon. Emerg Infect Dis. 2007, 13: 1125-1126. 10.3201/eid1307.061386.

Douglas N, Nicholas N, Angus B, Nosten F, Price R: Artemisinin combination therapy for vivax malaria. Lancet Infect Dis. 2010, 10: 405-416. 10.1016/S1473-3099(10)70079-7.